Last reviewed · How we verify
Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone in Paediatric Patients - a Retrospective, Real-life Observational Study in a uk Primary Care Asthma Population
The primary aim of this study was to compare the absolute and relative effectiveness of asthma management in paediatric patients in the UK on inhaled corticosteroid (ICS) maintenance therapy as extra-fine HFA-BDP (Qvar®) pressurised metered dose inhaler (pMDI) compared with fluticasone propionate (FP) pMDI.
Details
| Lead sponsor | Research in Real-Life Ltd |
|---|---|
| Status | COMPLETED |
| Enrolment | 2654 |
| Start date | 2011-02 |
| Completion | 2013-03 |
Conditions
- Asthma
Interventions
- Extra-fine hydrofluoroalkane beclometasone dipropionate
- Fluticasone propionate
Primary outcomes
- Proxy risk domain asthma control — One year outcome period
Defined as the absence of the following during the one-year outcome period: 1. Asthma-related: * Hospital attendance or admission, OR * A\&E attendance, OR * Out of hours attendance, OR * Out-patient department attendance 2. GP consultations for lower respiratory tract infection 3. Prescriptions for acute courses of oral steroids . - Asthma exacerbation rate ratio — One year outcome period
Where exacerbations are defined as an occurrence of: Defined as an occurrence of: 1. Asthma related: * Hospital admission, OR * A\&E attendance, OR 2. Use of acute oral steroids.